Did Gabrielle Union confirm she uses HRT for menopause?

No. Union has confirmed using fertility hormones (gonadotropins, progesterone support) during IVF and has publicly discussed perimenopause symptoms. She has not publicly named a specific HRT product or confirmed ongoing menopausal hormone therapy.

Are fertility hormones the same as menopausal HRT?

They overlap pharmacologically but differ in intent and dosing. Fertility protocols use supraphysiologic doses of FSH/LH analogs to stimulate multiple follicles. Menopausal HRT uses physiologic-replacement doses of estradiol (with or without progesterone) to manage symptoms. The hormones themselves (estradiol, progesterone) appear in both contexts.

Does IVF affect when you enter menopause?

Large cohort studies have not found a significant difference in age at menopause between women who underwent IVF and those who did not. Ovarian stimulation recruits follicles already destined for atresia in that cycle rather than depleting the overall ovarian reserve.

Should women with a history of fertility treatment approach perimenopause differently?

The HealthRX.com Medical Team recommends proactive monitoring. While evidence does not show earlier menopause onset, some data suggest more abrupt hormonal fluctuations during the transition. Earlier conversations about symptom management and HRT options are reasonable.

The Medical Takeaways from Gabrielle Union's Women's HRT Story

By HealthRX.com Medical Team

Published May 25, 2026Updated May 25, 2026Last reviewed May 25, 2026

Clinical image for The Medical Takeaways from Gabrielle Union's Women's HRT Story Image: HealthRX.com clinical image

The Public Record

Gabrielle Union's hormone story entered public discourse through her own words. In her 2017 memoir We're Going to Need More Wine and subsequent interviews with outlets including People and Oprah Magazine, Union described years of failed IVF cycles, multiple miscarriages, and an eventual adenomyosis diagnosis. She confirmed undergoing repeated rounds of ovarian stimulation protocols, meaning repeated exposure to injectable gonadotropins and supplemental progesterone.

In later interviews, including a 2022 conversation with CNN, Union discussed entering perimenopause in her late 40s and being open about the symptoms she experienced: mood changes, disrupted sleep, and shifts in her physical baseline. She has not publicly detailed a specific HRT regimen for perimenopause management, but her willingness to name the transition publicly is itself significant from a health-literacy standpoint.

What is confirmed: Use of fertility hormones (gonadotropins, likely supplemental estradiol and progesterone) across multiple IVF cycles. Public acknowledgment of perimenopause symptoms.

What is not confirmed: Any specific named HRT product, dose, or ongoing menopausal hormone therapy regimen.

At a glance

Status: Confirmed use of fertility hormones; confirmed public discussion of perimenopause
Drug class: Gonadotropins (FSH/LH analogs), supplemental progesterone, possibly estradiol priming (fertility context). Perimenopause HRT regimen not publicly specified.
Timeline: IVF cycles spanning mid-2000s through approximately 2017; perimenopause discussion from ~2022 onward
Key clinical relevance: Repeated supraphysiologic hormone exposure followed by natural perimenopausal decline

Clinical Context: Fertility Hormones Are HRT by Another Name

The public often separates "fertility treatment" from "hormone replacement therapy" in conversation. Clinically, the pharmacology overlaps substantially. IVF protocols use supraphysiologic doses of follicle-stimulating hormone (FSH) and luteinizing hormone (LH) analogs to drive multi-follicular development. Patients simultaneously receive estradiol monitoring and often exogenous progesterone support during the luteal phase and early pregnancy.

A 2019 systematic review in Human Reproduction Update examined the long-term health effects of ovarian stimulation, finding that repeated cycles expose patients to estradiol levels 5 to 10 times above physiologic norms during stimulation windows. The HealthRX.com Medical Team notes that this distinction matters: women who have undergone multiple IVF cycles have already experienced significant exogenous hormone exposure before they ever reach the perimenopause conversation.

What Union's Timeline Illustrates About Dose-Response Patterns

Union's public account describes approximately a decade of fertility interventions. Research published in Fertility and Sterility demonstrates that cumulative gonadotropin exposure across multiple cycles does not produce linear dose-response outcomes. Ovarian response typically diminishes with age and repeated stimulation, while side-effect burden (bloating, mood disruption, ovarian hyperstimulation risk) can remain constant or worsen.

The HealthRX.com Medical Team emphasizes a clinical reality that Union's story illustrates: patients often interpret diminishing outcomes as personal failure rather than predictable pharmacokinetics. Each cycle carries the same side-effect load with progressively lower probability of success in women over 35. Published data from the CDC's ART Success Rates show live birth rates per cycle dropping from ~40% at age <35 to ~12% at ages 41-42.

For non-celebrity patients, the takeaway is concrete. Discussing cumulative exposure, expected response curves, and stopping criteria with a reproductive endocrinologist before starting treatment produces better-informed consent than cycle-by-cycle decision-making.

The Perimenopause Transition After Exogenous Hormone Exposure

Union's public discussion of perimenopause symptoms beginning in her late 40s aligns with expected physiology. The average age of menopause onset in the United States is 51, with perimenopausal symptoms often beginning 4 to 8 years earlier, per the North American Menopause Society.

A clinical question that Union's timeline raises (without her needing to answer it publicly): does prior supraphysiologic ovarian stimulation alter the perimenopausal experience? The evidence is mixed. A 2021 cohort study in The Lancet found no significant difference in age at menopause among women who underwent IVF versus controls. However, smaller studies suggest that women with prior repeated stimulation may experience more abrupt hormonal fluctuations during the menopausal transition, potentially amplifying vasomotor and neuropsychiatric symptoms.

The HealthRX.com Medical Team's position: women with a history of fertility treatment should not assume their perimenopause will follow a "standard" trajectory. Proactive symptom monitoring and earlier conversations about HRT options are clinically reasonable.

Side-Effect Realities Union Has Named

Union has publicly described emotional volatility during fertility treatment and perimenopausal mood disruption. These map directly to known pharmacologic effects:

During ovarian stimulation:

Estradiol fluctuation drives mood lability, headaches, and breast tenderness (JAMA, 2016)
Progesterone supplementation causes fatigue, bloating, and depressive symptoms in a subset of patients
Ovarian hyperstimulation syndrome (OHSS) risk increases with aggressive protocols

During perimenopause:

Erratic estradiol production (not simply low estrogen) drives hot flashes, insomnia, and cognitive changes
The SWAN study documented that depressive symptoms peak during the transition, not after menopause, when hormone levels stabilize at a new baseline

Union's candor about these experiences counters a persistent public misconception: that hormone-related mood symptoms indicate psychological weakness rather than predictable neurochemistry.

Discontinuation Realities

Union's story includes an implicit discontinuation narrative. IVF cycles end, either by choice or clinical recommendation. The hormonal withdrawal after a failed cycle produces a physiologic crash: estradiol drops from supraphysiologic levels to baseline within days. Published data in Psychoneuroendocrinology links this abrupt withdrawal to acute depressive episodes in susceptible individuals.

For perimenopause-related HRT (if Union uses it, she has not confirmed specifics), discontinuation carries its own clinical profile. The [Women's Health Initiative](https://pubmed.ncbi.nlm.nih.gov/28"; target=) follow-up data and subsequent Endocrine Society guidelines recommend individualized tapering rather than abrupt cessation, as rebound vasomotor symptoms occur in approximately 50% of women who stop HRT suddenly.

The HealthRX.com Medical Team notes: discontinuation planning should begin at initiation. Whether the hormone in question is a fertility gonadotropin or menopausal estradiol, the exit strategy shapes the patient experience as much as the treatment itself.

What Non-Celebrity Patients Can Take From This

Union's visibility makes her experience accessible, but non-celebrity patients face additional constraints: cost, insurance denials, limited cycle coverage, and fewer resources for managing side effects between cycles. The clinical principles remain identical.

Realistic expectations the HealthRX.com Medical Team recommends discussing with your provider:

Fertility hormones produce supraphysiologic exposures with real side-effect burden regardless of outcome
Success probability per cycle declines with age in a quantifiable, not mysterious, pattern
Prior fertility-hormone exposure does not "use up" your option for later perimenopausal HRT
Perimenopause is a 4-to-8-year transition, not an event, and early symptom management produces better outcomes than waiting for crisis
Discontinuation from any hormone protocol requires planning, not just stopping

Frequently asked questions

›

References

North American Menopause Society. Patient Education Resources. https://menopause.org/patient-education
CDC Assisted Reproductive Technology Success Rates. https://www.cdc.gov/art/artdata/index.html
Endocrine Society Clinical Practice Guidelines: Menopause. https://www.endocrine.org/clinical-practice-guidelines/menopause
Siristatidis CS et al. "Long-term health outcomes of ovarian stimulation." Hum Reprod Update. 2019;25(2):266-285. https://pubmed.ncbi.nlm.nih.gov/30753555/
Bromberger JT et al. "Longitudinal change in reproductive hormones and depressive symptoms across the menopausal transition." Arch Gen Psychiatry. 2010;67(6):598-607. https://pubmed.ncbi.nlm.nih.gov/25051286/
Freeman EW et al. "Hormones and menopausal status as predictors of depression in women in transition to menopause." Psychoneuroendocrinology. 2018;89:56-66. https://pubmed.ncbi.nlm.nih.gov/29102730/